QRX 003
Alternative Names: QRX-003Latest Information Update: 08 Aug 2024
At a glance
- Originator Quoin Pharmaceuticals
- Class Anti-inflammatories; Skin disorder therapies; Small molecules
- Mechanism of Action Serine protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Netherton Syndrome
- Preclinical Palmoplantar keratoderma; Skin disorders
Most Recent Events
- 08 Aug 2024 Quoin Pharmaceuticals plans clinical trial in Peeling skin syndrome (In Children) in New Zealand (Topical)
- 23 Apr 2024 Endo International has been acquired and merged into Endo, Inc.
- 04 Mar 2024 Quoin Pharmaceuticals receives FDA clearance in its two ongoing trials in Netherton syndrome to after 14 years and above